title: The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa.
abstract: OBJECTIVE
  We hypothesize that time to initiate care and maturity of a treatment program impact on outcome of severely immuno-compromised patients with higher risk of mortality.
  
  
  METHODS
  We conducted a retrospective cohort analysis at the Perinatal HIV Research Unit Adult ART clinic, Soweto, South Africa.
  
  
  METHODS
  ELIGIBILITY CRITERIA FOR THIS ANALYSIS WERE: attendance for minimum one visit between August 2004 and August 2010, age >18 years, CD4 count < 50 cells/mm(3) and ART-naïve at screening. We followed participants up to one year after ART initiation. We defined years 2004-2007 and 2008-2010 as the early and late eras respectively. Chi-square test and survival analysis methods were used for mortality comparisons between eras.
  
  
  RESULTS
  Of 2357 patients eligible for antiretroviral treatment, 395 (17%) had CD4 counts < 50 cells/mm(3) and ART-naïve at screening. Overall 261 (66%) were women. Patients had similar median age (35 vs. 33.5 years, p=0.08), time to HAART initiation (7 days, p=0.18) and baseline CD4 count (20 vs. 23 cells/mm(3), p=0.5) between eras. Overall 63 (16%) patients died in their first year of treatment (2 per 100 person-months) and the main cause of death was tuberculosis (n=23, 37%). The proportion of deaths (52/262 vs. 11/133, p=0.003) and time to death from enrolment (logrank p=0.04) were significantly different between eras.
  
  
  CONCLUSIONS
  Mortality decreased as the ART program matured in Soweto while time to initiation of treatment remained similar in both eras. Because ART guidelines were consistent during both eras, it is possible that with time, management of patients improved as expertise was gained.
authors: Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, Gauteng, South Africa.
authors: Kennedy N
authors: KN
authors: Otwombe
authors: Fatima
authors: F
authors: Laher
authors: Thandeka
authors: T
authors: Tutu-Gxashe
authors: Glenda
authors: G
authors: Gray
authors: Lerato
authors: L
authors: Mohapi
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality*; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D008297:Male; D012189:Retrospective Studies; D012306:Risk; D013019:South Africa
chemical_list: D019380:Anti-HIV Agents